BRIEF-Regenxbio Announces FDA Review Extension Of BLA For RGX-121 To Treat Patients With MPS II

Reuters
Aug 19
BRIEF-Regenxbio Announces FDA Review Extension Of BLA For RGX-121 To Treat Patients With MPS II

Aug 18 (Reuters) - Regenxbio Inc RGNX.O:

  • REGENXBIO ANNOUNCES FDA REVIEW EXTENSION OF BLA FOR RGX-121 TO TREAT PATIENTS WITH MPS II

  • REGENXBIO INC - PDUFA DATE EXTENDED TO FEBRUARY 8, 2026

Source text: ID:nPn5DTxK3a

Further company coverage: RGNX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10